Seguir
Jörg Mahlich
Jörg Mahlich
Düsseldorf
Email confirmado em dice.hhu.de - Página inicial
Título
Citado por
Citado por
Ano
Understanding the global measurement of willingness to pay in health
JA McDougall, WE Furnback, B Wang, J Mahlich
Journal of market access & health policy 8 (1), 1717030, 2020
1002020
The determinants of pharmaceutical R&D expenditures: evidence from Japan
JC Mahlich, T Roediger-Schluga
Review of Industrial Organization 28, 145-164, 2006
672006
Pharmaceutical regulation in Europe and its impact on corporate R&D
S Eger, JC Mahlich
Health economics review 4, 1-9, 2014
562014
Economic burden of osteoporotic fractures in Austria
HP Dimai, K Redlich, M Peretz, F Borgström, U Siebert, J Mahlich
Health economics review 2, 1-10, 2012
562012
Persistence with biologic agents for the treatment of rheumatoid arthritis in Japan
J Mahlich, R Sruamsiri
Patient preference and adherence, 1509-1519, 2016
522016
Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany
J Zeidler, J Mahlich, W Greiner, S Heres
Applied health economics and health policy 11, 509-521, 2013
522013
Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
R Sruamsiri, K Iwasaki, W Tang, J Mahlich
BMC dermatology 18, 1-11, 2018
462018
Estimating prevalence and healthcare utilization for treatment-resistant depression in Japan: a retrospective claims database study
J Mahlich, S Tsukazawa, F Wiegand
Drugs-Real World Outcomes 5, 35-43, 2018
452018
Evaluating the Concordance of Physician Judgments and Patient Preferences on AIDS/HIV Therapy - A Discrete Choice Experiment
A Mühlbacher, M Stoll, J Mahlich, M Nübling
Health Economics Review 3 (30), 2013
442013
Patents and performance in the Japanese pharmaceutical industry: An institution-based view
JC Mahlich
Asia Pacific Journal of Management 27 (1), 99-113, 2010
412010
Shared decision-making in patients with prostate cancer in Japan: patient preferences versus physician perceptions
U Schaede, J Mahlich, M Nakayama, H Kobayashi, Y Takahashi, K Saito, ...
Journal of Global Oncology 4, 1-9, 2017
342017
Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data
H Kuwabara, Y Saito, J Mahlich
Neuropsychiatric disease and treatment, 935-940, 2015
342015
Unemployment, health, and education of HIV-infected males in Germany
M Groß, A Herr, M Hower, A Kuhlmann, J Mahlich, M Stoll
International journal of public health 61, 593-602, 2016
332016
Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus: A structural equation modeling approach
R Sruamsiri, H Kubo, J Mahlich
Medicine 97 (29), e11491, 2018
312018
Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany-an application of the efficiency frontier approach
C Gissel, G Götz, J Mahlich, H Repp
BMC infectious diseases 15, 1-9, 2015
312015
Innovation and technology in Korea: Challenges of a newly advanced economy
J Mahlich, W Pascha
Springer Science & Business Media, 2007
312007
Drug survival of biological therapies for psoriasis treatment in Germany and associated costs: a retrospective claims database analysis
J Mahlich, A Alba, LE Hadad, MK Leisten, WK Peitsch
Advances in therapy 36, 1684-1699, 2019
302019
Cultural beliefs, utility values, and health technology assessment
J Mahlich, P Dilokthornsakul, R Sruamsiri, N Chaiyakunapruk
Cost Effectiveness and Resource Allocation 16, 1-8, 2018
302018
Productivity loss of Japanese patients with rheumatoid arthritis–a cross-sectional survey
R Sruamsiri, J Mahlich, E Tanaka, H Yamanaka
Modern rheumatology 28 (3), 482-489, 2018
292018
Drug utilization of Japanese patients diagnosed with schizophrenia: an administrative database analysis
S Cheung, Y Hamuro, J Mahlich, T Nakahara, R Sruamsiri, S Tsukazawa
Clinical Drug Investigation 37, 559-569, 2017
282017
O sistema não pode efectuar a operação agora. Tente mais tarde.
Artigos 1–20